China leads the world with the highest number of research publications on traditional, complementary, and integrative medicines (TCIMs) in relation to COVID-19 clinical trials, followed by India, US, and Iran.
The Medical Board of Australia's (MBA) proposal to reassess the regulation of complementary medicines and practitioners who prescribe them has elicited a strongly worded response from Marcus Blackmore.
Almost 60% of complementary healthcare practitioners in Australia think recent reforms by the Therapeutic Good Administration (TGA) have had an adverse impact on the industry, according to the regulator's own stakeholder survey.
Australia is recognised as a premium industry in the complementary medicine sector, and upcoming new regulations will help enhance its reputation for quality, safety and innovation, writes Complementary Medicines Australia (CMA) CEO Carl Gibson.
When Complementary Medicines Australia (CMA) conducted its inaugural audit of the Australian complementary medicines sector in 2011 estimated industry revenue was $AU1.9 billion, now the value of sales stand $ at 4.7 billion.
There is a once in a generation opportunity to achieve a balance between pre and post market activities for supplements regulations in Australia, writes Emma Burchell, head of Regulatory Affairs for Complementary Medicines Australia.
The Chinese health food and supplements market is valued at US$30 billion and projected to grow by 10% every year until 2025, creating extensive opportunities for Australian firms, writes Carl Gibson, CEO of Complementary Medicines Australia.
Trade body Complementary Medicines Australia (CMA) has insisted consumers can have full confidence in products purchased in Australia after a new review claimed it was a 'misperception' that herbal medicines are safe.